Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Manuela
M
Balocco
Paola
P
Carrara
Valeria
V
Pinto
Gian Luca
GL
Forni
D000284:Administration, Oral; D018771:Arthralgia / Q000139:chemically induced; D001565:Benzoates / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D015913:Chelation Therapy / Q000379:methods*; D000077588:Deferasirox; D000077543:Deferiprone; D003676:Deferoxamine / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D055104:Infusions, Subcutaneous; D007502:Iron Chelating Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D019190:Iron Overload / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D011728:Pyridones / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D065227:Transfusion Reaction; D014230:Triazoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D055815:Young Adult; D017086:beta-Thalassemia / Q000097:blood / Q000628:therapy*
D001565:Benzoates; D007502:Iron Chelating Agents; D011728:Pyridones; D014230:Triazoles; D000077543:Deferiprone; D003676:Deferoxamine; D000077588:Deferasirox